SynthesisBMC psychiatry2025
Effect of n-3 polyunsaturated fatty acids on the treatment of schizophrenia: an updated systematic review and meta-analysis.
Synthesis in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polyunsaturated fatty acids and psychotic disorders: integrating mechanistic, genetic, and clinical evidence.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia is a chronic disorder, and treatment options for its negative and cognitive symptoms are limited. Omega-3 fatty acids have potential neuroprotective effects, but evidence of their efficacy in schizophrenia and ultra-high risk group is inconsistent. This study aimed to provide an updated meta-analysis of randomized controlled trials evaluating the effectiveness of omega-3 fatty acid supplementation in patients with schizophrenia and ultra-high risk group.
methodsA PRISMA-guided meta-analysis of randomized controlled trials comparing omega-3 fatty acids with placebo in schizophrenia was conducted. The literature search was concluded on November 12, 2024, and was conducted without any restrictions on language or timeframe. Data were extracted and analyzed using fixed or random-effects model depending on heterogeneity. Subgroup, sensitivity, and bias assessments were performed.
resultsThe meta-analysis, which included 16 trials with 1,435 participants, revealed no significant difference between omega-3 fatty acids and placebo in schizophrenia at the endpoint of intervention (standard mean difference = - 0.123; 95% confidence interval = - 0.267 to 0.021; p = 0.095), and ultra-high risk of schizophrenia at the endpoint of follow-up after intervention (standard mean difference = - 0.070; 95% confidence interval = - 0.425 to 0.285; p = 0.699). A small number of subgroup analyses suggested potential benefits for patients with first-episode schizophrenia and treatment over 24 weeks, and those receiving adjunctive antioxidant treatment. Publication bias was minimal.
conclusionsOmega-3 fatty acid supplementation generally has no significant benefits for treating schizophrenia and ultra-high risk group. However, subgroup findings highlight the need for future trials focusing on early-stage patients, longer supplementation, and exploring synergistic effects with adjunctive antioxidant interventions. Clinical application should remain cautious until further confirmatory evidence emerges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.